Ready_For_The_Unexpected

For adults.
Not an actual patient.

Relapsing multiple sclerosis (MS) is unpredictable and patients’ health considerations may change over time.2,3 An agile treatment plan can help you adapt to your patients’ needs.3

With PONVORY®, you can be ready to help manage certain unexpected events your adult patients may face along their MS journeys, including relapses and lesions or needing to pause therapy for infections, vaccines, or family planning.1

S1P = sphingosine-1-phosphate; SSRI = selective serotonin reuptake inhibitor.

*In the phase 3, ~108-week OPTIMUM study vs Aubagio® (teriflunomide), PONVORY® was shown to reduce the average number of relapses per year and the average number of new gadolinium-enhancing T1 and new or enlarging T2 lesions.1,4

As measured by time to 3-month confirmed disability progression. There was no statistically significant difference between the PONVORY® and Aubagio® groups.1

Includes the OPTIMUM study and the phase 2, 6-month, placebo-controlled study and the uncontrolled extension studies.1

§PONVORY® must be stopped in cases of pregnancy. Advise a female patient to immediately inform you if she is pregnant or planning to become pregnant.1

No elimination procedure required.1

#As in pharmacokinetic-pharmacodynamic assessments.1

||If 4 or more consecutive doses of PONVORY® are missed, treatment should be re-initiated with Day 1 of the titration regimen using a new 14-Day Starter Pack. First dose monitoring should also be completed in patients for whom it is recommended.1

**Collected in 7/22 and is subject to change. Within 2% of access being stated. This information does not provide advice or guarantee coverage or payment, is not intended to provide reimbursement advice, and is not intended to increase or maximize reimbursement by any payer. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply. This may not represent 100% of formulary lives due to data limitations.9